Table 1.
Clinical features of the RA and PsA patients and the administered therapy. The table reports the main clinical features of each patient and the complete list of failed therapies. Failed b-DMARDs and ts-DMARDs are divided into three columns according to the reason that led to therapy discontinuation (e.g., primary inefficacy, secondary inefficacy, adverse effects requiring therapy suspension). (F = female; M = male; RA = rheumatoid arthritis; PsA = psoriatic arthritis; RF = rheumatoid factor; ACPA = anticitrullinated peptide/protein antibodies).
| Subject (Gender) |
Age (Age at Disease Onset) |
Disease | Seropositivity | Autoimmune/ Inflammatory Comorbidities |
Failed cs-DMARDs |
b-/ts-DMARDs Primary Inefficacy |
b-/ts-DMARDs Secondary Inefficacy |
b-/ts-DMARDs Adverse Event |
|---|---|---|---|---|---|---|---|---|
| SP1 (F) |
73 (60) |
RA | RF + ACPA | Secondary Sjögren’s syndrome |
methotrexate cyclosporine leflunomide | adalimumab etanercept baricitinib | abatacept | tocilizumab (neutropenia) |
| SP2 (F) |
61 (47) |
RA | RF + ACPA | - | methotrexate leflunomide | abatacept | rituximab certolizumab | etanercept (skin reaction) |
| SP3 (F) |
60 (50) |
RA | RF + ACPA | - | leflunomide methotrexate | rituximab tocilizumab |
certolizumab adalimumab etanercept abatacept |
baricitinib (serious infection) |
| SP4 (F) |
54 (38) |
RA | RF + ACPA | IgA nephropathy |
methotrexate leflunomide sulphasalazine | adalimumab golimumab certolizumab abatacept baricitinib | etanercept tocilizumab | |
| SP5 (F) |
48 (36) |
RA | ACPA | - | methotrexate leflunomide | adalimumab abatacept baricitinib rituximab sarilumab | etanercept | tocilizumab (serious infection) |
| SN1 (F) |
56 (36) |
RA | Negative | Psoriasis | methotrexate leflunomide cyclosporine | etanercept rituximab abatacept tocilizumab |
baricitinib adalimumab infliximab golimumab |
anakinra (skin reaction) |
| SN2 (F) |
60 (54) |
RA | Negative | - | methotrexate leflunomide | tocilizumab | etanercept adalimumab | |
| SN3 (F) |
35 (34) |
PsA | Negative | - | cyclosporine | infliximab ixekizumab | adalimumab (paradoxical psoriasis) |
|
| SN4 (F) |
29 (26) |
PsA | Negative | - | methotrexate | infliximab adalimumab | secukinumab | |
| SN5 (M) |
59 (48) |
RA | Negative | - | methotrexate leflunomide | abatacept etanercept baricitinib anakinra tofacitinib |
tocilizumab sarilumab adalimumab infliximab | |
| SN6 (F) | 54 (27) |
RA | Negative | - | methotrexate cyclosporine leflunomide sulphasalazine | etanercept tocilizumab abatacept | baricitinib infliximab adalimumab golimumab certolizumab |